DBV Technologies SA

DBV Technologies to Participate in Upcoming EAACI Congress 2025

12 يونيو 2025 13:05:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

11 يونيو 2025 13:30:00 بحسب Nasdaq GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

04 يونيو 2025 13:32:09 بحسب Nasdaq GlobeNewswire

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

03 يونيو 2025 13:30:00 بحسب Nasdaq GlobeNewswire

Combined General Meeting of June 11, 2025

15 مايو 2025 13:30:00 بحسب Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025

06 مايو 2025 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

05 مايو 2025 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Reports First Quarter 2025 Financial Results

30 أبريل 2025 13:00:00 بحسب Nasdaq GlobeNewswire

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

11 أبريل 2025 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

27 مارس 2025 19:30:05 بحسب Nasdaq GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

23 مارس 2025 23:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

25 فبراير 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

13 يناير 2025 13:05:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

08 يناير 2025 13:05:00 بحسب Nasdaq GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

11 ديسمبر 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024

02 ديسمبر 2024 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Plan to Implement ADS Ratio Change

11 نوفمبر 2024 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter 2024 Financial Results

06 نوفمبر 2024 13:30:00 بحسب Nasdaq GlobeNewswire

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

22 أكتوبر 2024 13:45:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

18 أكتوبر 2024 13:30:00 بحسب Nasdaq GlobeNewswire